pan-Canadian Pharmaceutical Alliance (pCPA): November 2019 Trends and Insights The pan-Canadian Pharmaceutical Alliance (pCPA) has issued the November 30, 2019 status of brand negotiations. Highlights since the last update include: 6 products completed CADTH review, for a total of 9 files under consideration; 4 products initiated pCPA negotiations, for a total of 34 active negotiations; 12 negotiations completed for a total of 294 … Read More →
Summary of the CADTH Drug Portfolio Information Session November 2019
Summary of CADTH Drug Portfolio Information Session Date: Monday, November 25, 2019 Time: 1:30 pm to 4:00 pm On November 25, 2019, CADTH hosted two information sessions in Toronto, Ontario for their Medical Device and Drug Portfolios. These annual sessions are an opportunity for stakeholders to get the latest information about priority initiatives and process changes. The summary below is separated into the … Read More →
RWE and OBA Working Group 2019 Findings & Executive Summary
a[href$=”.pdf”] { background: transparent url(https://morseconsulting.ca/images/pdf-link.gif) no-repeat center right 11px; The 2019 Real-World Evidence and Outcomes-Based Agreements Working Group research and outputs executive summary report is now available. Download The Report The mission of the Real-World Evidence and Outcomes-Based Agreements Working Group is to advance the opportunity for the use of outcomes-based agreements in Canada. The working group’s 2019 primary focus was … Read More →
The workload at pCPA appears to have stabilized over 2019
pan-Canadian Pharmaceutical Alliance (pCPA): October 2019 Trends and Insights The pan-Canadian Pharmaceutical Alliance (pCPA) has issued the October 31, 2019 status of brand negotiations. Highlights since the last update include: 4 products completed CADTH review, for a total of 7 files under consideration; 2 products initiated pCPA negotiations, for a total of 42 active negotiations; 6 negotiations completed for a total of 282 … Read More →
Update on the CanREValue Collaboration
Development of a framework for the generation and use of Real-World Evidence for cancer drug funding. The CanREValue Collaboration hosted a webinar on November 6, 2019 to introduce their preliminary framework and to outline the Stakeholder Feedback process. The slide deck that was presented, along with a recording can be accessed from the CanREValue website. The purpose of the CanReValue Collaboration is to … Read More →
Average Time Under pCPA Consideration Below 30 Days for the 3rd Consecutive Month
pan-Canadian Pharmaceutical Alliance (pCPA): September 2019 Trends and Insights The pan-Canadian Pharmaceutical Alliance (pCPA) has issued the September 30, 2019 status of brand negotiations. Highlights since the last update include: 4 products completed CADTH review, for a total of 6 files under consideration; 8 products initiated pCPA negotiations, for a total of 48 active negotiations; 6 negotiations completed for a total of 276 … Read More →
NEW Canadian Reimbursement Trends and Timelines Report – now available!
Toronto, September 18, 2019 – MORSE Consulting is pleased to launch the Canadian Reimbursement Trends and Timelines report – a comprehensive, credible and relevant source of market access intelligence. The market access pathway in Canada is going through an unprecedented level of change and uncertainty. This 58-page PowerPoint report is aimed at not only helping market access professionals plan for future launches but can … Read More →
15 Oncology Files either Completed, Initiated or new Under Consideration
pan-Canadian Pharmaceutical Alliance (pCPA): August 2019 Trends and Insights The pan-Canadian Pharmaceutical Alliance (pCPA) has issued the August 31, 2019 status of brand negotiations. Highlights since the last update include: 5 products completed CADTH review, for a total of 13 files under consideration; 8 products initiated pCPA negotiations, for a total of 47 active negotiations; 7 negotiations completed for a total of 270 … Read More →
Potential Impact of PMPRB Changes from a Regulatory, HTA and Payer Perspective
Introduction MORSE Consulting is pleased to contribute its pCPA/public payer expertise with leading pricing and reimbursement experts and provide our respective views on how the new PMPRB regulations may impact the Canadian environment. These experts include: PMPRB: Joan McCormick, Principal Consultant – IQVIA HTA/Health Economics (HE): Sumeet Singh & Heather Cameron – Cornerstone Research Group Inc. Private Payers: Suzanne Lepage, Suzanne Lepage Consulting The … Read More →
CADTH Pharmaceutical Reviews Update – July 2019
MORSE Consulting summary of CADTH update. On July 31, 2019 CADTH released its Pharmaceutical Reviews Update – Issue 9 and MORSE Consulting has prepared a brief summary of the important developments from this CADTH update. Consultations (Feedback to be provided by September 13, 2019) CADTH is inviting stakeholder comments and feedback on three proposals for the Pharmaceutical Review Programs. 1) Enhance the Transparency … Read More →
pCPA Closing More Negotiations Without Agreements
pan-Canadian Pharmaceutical Alliance (pCPA): July 2019 Trends and Insights The pan-Canadian Pharmaceutical Alliance (pCPA) has issued the status of brand negotiations as of July 31, 2019. Highlights since the last update include: 5 products completed CADTH review, for a total of 12 files under consideration; 7 products initiated pCPA negotiations, for a total of 47 active negotiations; 6 negotiations completed for a total … Read More →
Number of Active Negotiations (49) at Highest Level Since November 2018
pan-Canadian Pharmaceutical Alliance (pCPA): June 2019 Trends and Insights The pan-Canadian Pharmaceutical Alliance (pCPA) has issued the status of brand negotiations as of June 30, 2019. Highlights since the last update include: 6 products completed CADTH review, for a total of 15 files under consideration; 9 products initiated pCPA negotiations, for a total of 49 active negotiations; 4 negotiations completed for a total … Read More →
The pCPA Initiates Negotiations for a Second “Group” of Oncology Biosimilars
pan-Canadian Pharmaceutical Alliance (pCPA): May 2019 Trends and Insights The pan-Canadian Pharmaceutical Alliance (pCPA) has issued the status of brand negotiations as of May 31, 2019. Highlights since the last update include: 2 negotiations completed for a total of 253 completed negotiations; 2 negotiations closed, for a total of 37 closed negotiations; 1 file closed without negotiations, for a total of 65 declined … Read More →
April 2019 pCPA Update: The pCPA has completed over 250 negotiations
pan-Canadian Pharmaceutical Alliance (pCPA): April 2019 Negotiation Status Update The pan-Canadian Pharmaceutical Alliance (pCPA) has issued the status of brand negotiations as of April 30, 2019. Highlights since the last update include: 4 negotiations completed for a total of 251 completed negotiations No negotiations closed, for a total of 35 closed negotiations 1 file closed without negotiations, for a total of 64 declined … Read More →
March 2019 pCPA Update: Two negotiations initiated prior to completion of CADTH process
pan-Canadian Pharmaceutical Alliance (pCPA): March 2019 Negotiation Status Update The pan-Canadian Pharmaceutical Alliance (pCPA) has issued the status of brand negotiations as of March 31, 2019. Highlights since the last update include: 5 negotiations completed for a total of 247 completed negotiations 2 negotiations closed, for a total of 35 closed negotiations No new files closed without negotiations, for a total of 63 … Read More →
MORSE Consulting Inc. | Deciphering pharmaceutical market access signals to create reimbursement success.
© 2019 MORSE Consulting Inc. All rights reserved. |
Site by Directica Media
MORSE Market Access Signals - Latest in Pharmaceutical Reimbursement
